Evoke Drug Patent Portfolio
Evoke owns 1 orange book drug protected by 8 US patents Given below is the list of Evoke's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12377064 | 17 Nov, 2038 | Active | |
| US8334281 | Nasal formulations of metoclopramide | 16 May, 2030 | Active |
| US11020361 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US11628150 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US11813231 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US12194008 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US12194009 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US6770262 | Nasal administration of agents for the treatment of gastroparesis | 29 Mar, 2021 | Expired |
Latest Legal Activities on Evoke's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Evoke.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jun, 2024 | US8334281 |
|
Email Notification
Critical
| 08 Dec, 2023 | US8334281 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Dec, 2023 | US8334281 |
|
Email Notification
Critical
| 01 Dec, 2023 | US11020361 |
|
Email Notification
Critical
| 01 Dec, 2023 | US11813231 |
|
Email Notification
Critical
| 01 Dec, 2023 | US11628150 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Dec, 2023 | US11813231 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Dec, 2023 | US11628150 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Dec, 2023 | US11020361 |
| Mail Patent eGrant Notification | 14 Nov, 2023 | US11813231 |
|
Email Notification
Critical
| 14 Nov, 2023 | US11813231 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Nov, 2023 | US11813231 |
| Recordation of Patent eGrant | 14 Nov, 2023 | US11813231 |
| Patent eGrant Notification | 14 Nov, 2023 | US11813231 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Nov, 2023 | US11813231 |
Evoke's Family Patents
Evoke Drug List
Given below is the complete list of Evoke's drugs and the patents protecting them.
1. Gimoti
Gimoti is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12377064 |
17 Nov, 2038
(12 years from now)
| Active | |
| US8334281 | Nasal formulations of metoclopramide |
16 May, 2030
(4 years from now)
| Active |
| US11020361 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US11628150 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US11813231 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US12194008 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US12194009 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US6770262 | Nasal administration of agents for the treatment of gastroparesis |
29 Mar, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gimoti's drug page